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Abstract
Background: Obstructive sleep apnea (OSA) is associated with obesity, insulin resistance (IR) and diabetes.
Continuous positive airway pressure (CPAP) rapidly mitigates OSA in obese subjects but its metabolic effects are
not well-characterized. We postulated that CPAP will decrease IR, ghrelin and resistin and increase adiponectin
levels in this setting.
Methods: In a pre- and post-treatment, within-subject design, insulin and appetite-regulating hormones were
assayed in 20 obese subjects with OSA before and after 6 months of CPAP use. Primary outcome measures
included glucose, insulin, and IR levels. Other measures included ghrelin, leptin, adiponectin and resistin levels.
Body weight change were recorded and used to examine the relationship between glucose regulation and
appetite-regulating hormones.
Results: CPAP effectively improved hypoxia. However, subjects had increased insulin and IR. Fasting ghrelin
decreased significantly while leptin, adiponectin and resistin remained unchanged. Forty percent of patients gained
weight significantly. Changes in body weight directly correlated with changes in insulin and IR. Ghrelin changes
inversely correlated with changes in IR but did not change as a function of weight.
Conclusions: Weight change rather than elimination of hypoxia modulated alterations in IR in obese patients with
OSA during the first six months of CPAP therapy.
Background
Obstructive sleep apnea (OSA) is characterized by sleep-
related airway obstructions that produce apnea. These
events provoke arousals and cause oxygen desaturations
and heightened sympathetic activity during sleep and
waking hours [1] that may play a role in the develop-
ment of insulin resistance [2]. Obesity is a strong risk
factor for OSA [3] and both obesity and OSA are asso-
ciated with increased insulin resistance and diabetes [4].
Hormones involved in the regulation of body weight
and glucose metabolism include ghrelin, leptin, adipo-
nectin and resistin. Ghrelin is an orexigenic hormone
and it has been proposed as a cause of increased appe-
tite and obesity [5]. Administration of ghrelin increases
adiposity, food intake and body weight [6]. It also regu-
lates glucose homeostasis increasing glucose levels and
decreasing insulin secretion [7]. Leptin is a hormone
secreted by adipocytes in proportion to fat mass. It is
elevated in obesity and its administration suppresses
appetite and induces weight loss [8]. Resistin and adipo-
nectin are also adipocyte-derived hormones linked to
obesity, insulin resistance, and diabetes. Adiponectin
levels inversely correlate with BMI and are lower in
individuals with diabetes whereas resistin directly corre-
lates with obesity and insulin resistance.
Whether treatment of OSA can reverse insulin resis-
tance and prevent body weight gain is controversial.
Because hypoxemia-induced sympathetic activation is
thought to be the source of the endocrine abnormalities
often seen in patients with OSA, and continuous posi-
tive airway pressure (CPAP) effectively reverses hypoxe-
mia in patients with OSA, we hypothesized that CPAP
will decrease insulin resistance, ghrelin and resistin
levels and increase adiponectin levels in a group of
obese individuals with OSA.
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Study design and experimental subjects
The protocol was approved by the Baylor College of
Medicine Institutional Review Board, and the Research
and Development Committee of the Michael E. DeBakey
Veterans Affairs Medical Center in Houston, Texas. This
study was conducted between April 2004 and March
2006. All clinical investigati o nw a sc o n d u c t e di na c c o r -
dance with the guidelines in The Declaration of Helsinki
and all subjects provided written informed consent.
Adult subjects with no prior history of diabetes were
recruited from patients referred to the hospital’sS l e e p
Center for evaluation of OSA. OSA was confirmed by
laboratory polysomnography (PSG). Twenty-three
patients with an apnea+hypopnea index (AHI) ≥15
obstructive and/or mixed events/hour as criteria partici-
pated in the project. We did not enroll subjects with
AHI <15 because CPAP compliance in these patients
may not be optimal. For PSG, we scheduled bedtimes
and morning awakening times to resemble each partici-
pant’s usual habit. We made PSG recordings using
Grass Heritage computerized polysomnographic sys-
tems. Briefly, standard surface electrodes were used to
record electroencephalographic, electrooculographic,
electromyographic (submentalis and anterior tibialis),
and electrocardiographic activities. Nasal-oral thermo-
couples monitored airflow, while thoracic and abdom-
inal movements indicated respiratory effort. The
respiratory tracings were scored for the presence of
apneas (10-second, or longer, cessation in nasal-oral air-
flow) or hypopneas (a 10-second, or longer, reduction of
nasal-oral airflow of 30% or more with O2 desaturation
more than 4% or arousal). Blood oxygen saturation was
monitored with pulse oximetry. Recording and scoring
technique followed the current American Academy of
Sleep Medicine standards for human subjects. AHI was
calculated to indicate the number of sleep-disordered
breathing events/hour of sleep. Subjects qualifying for
study underwent an oral glucose tolerance test (OGTT)
and completed an Epworth Sleepiness Scale (ESS). After
this baseline evaluation, the subjects underwent an
attended CPAP titration with polysomnography. The
best pressure was the one associated with the lowest
AHI while the patient slept 20 minutes, or more. After
titration, subjects received a CPAP machine and related
accessories (Respironics, REMStar Pro) with card reader
to monitor the compliance of CPAP and were followed
for 6 months. Subjects were seen 2-3 times during the
study and CPAP compliance was checked during the
visits by using the EncorPro SmartCard (Respironics).
CPAP efficacy was rechecked with overnight pulse oxi-
metry at the end of the study. To mimic their real-life
situation, subjects were given no specific instructions
regarding diet or physical activity.
Hormonal assays
Blood was collected in the morning between 7 and 8
AM in EDTA-containing tubes and kept at 4°C during
processing. Aprotinin (100 μLc o n t a i n i n g0 . 6T I Up e r
mL of blood) was added to one of the tubes and the
samples were then centrifuged at 3000 rpm for 30 min-
utes. Active ghrelin levels were measured by a radioim-
munoassay (RIA) kit (LINCO Research, St. Charles,
MO) in plasma treated with HCL and phenylmethylsul-
fonyl-fluoride. Insulin and leptin levels were measured
by a radioimmunoassay kit (Linco Research, St. Charles,
MO) as we have previously described [9]. Glucose levels
were measured in the same plasma samples by the
MEDVAMC’s laboratory. Adiponectin levels were mea-
s u r e db yR I Aw i t hak i tf r o mL I N C OR e s e a r c h( S t .
Charles, MO) in diluted plasma samples (1:450). Resistin
was measured in plasma samples by ELISA (Biovendor,
Candler, NC).
Oral glucose tolerance test (OGTT) and assessment of
insulin sensitivity
The subjects underwent an early morning 75 g. OGTT
at baseline and after six months of CPAP therapy. Blood
samples were taken at -5, 30, 60, 90, and 120 min. for
the measurement of plasma active ghrelin, glucose and
insulin concentrations. Fasting insulin sensitivity was
assessed using the homeostasis model assessment
(HOMA) and the quantitative insulin sensitivity check
index (QUICKI). Both HOMA [HOMA-IR = fasting glu-
cose (mmol/L) × fasting insulin (microU/ml)/22.5] and
QUICKI (1/[log fasting insulin + log fasting glucose])
were calculated as previously described. Estimates of
insulin resistance from both indices correlate well with
estimates from the “gold standard” hyperinsulinemic
euglycemic clamp method [10,11]. In addition, from the
OGTT we calculated a previously validated index of
whole-body insulin sensitivity (ISI) (10,000/square root
of [fasting glucose × fasting insulin] × [mean glucose ×
mean insulin during OGTT]), which is highly correlated
(r = 0.73, p <0.0001) with the rate of whole-body glu-
cose disposal during the euglycemic insulin clamp [12].
Statistical Analysis
SPSS version 12.00 software for Windows (SPSS Inc.
Chicago, IL) was used for statistical analysis. Parametric
variables are expressed as mean ± S.E. unless otherwise
stated. Categorical parameters are expressed as percen-
tages. The areas under the curve (AUC0-120)f o ra c t i v e
ghrelin, insulin and glucose levels were calculated using
the trapezoidal rule. For normally distributed data, sta-
tistical comparisons were performed using the Fisher’s
exact test or Chi-square test for categorical data and t-
test for parametric data. Pearson’sc o r r e l a t i o n sw e r e
obtained between continuous variables. When data were
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Whitney tests were used and Spearman’s correlation
was obtained to measure associations between continu-
ous variables. Linear regression tested the predictive
value of changes in BMI and nadir SpO2 entered indivi-
dually on the following outcomes: changes in insulin,
insulin resistance as measured by HOMA-IR, leptin,
ghrelin, adiponectin and resistin. Inclusion was set at
probability F<0.05, and exclusion was set at F>0.10. Col-
linearity diagnostics used to test for multicollinearity
included tolerance, variance inflation factor and condi-
tion index. Inferential analysis was conducted using an
alpha error level of ≤0.05 to determine significance.
Power calculations were done using paired t-test, two-
sided methodology based on previously published insu-
lin sensitivity and ghrelin mean changes from baseline
where insulin sensitivity improved after 3 months of
CPAP by 1.37 mcmol/Kg × min [13] and ghrelin
decreased by 38.2 pg/mL after two days of CPAP [14] in
OSA patients. Assuming a SD of 1.7 mcmol/Kg × min
and 45 pg/mL respectively, we estimated that a sample
size of 23 subjects would be sufficient to detect statisti-
cally significant differences (p ≤ 0.05) in the outcomes
measured with a power of 90% and taking into account
an attrition rate of 15% (20 completers).
Results
Twenty-three subjects enrolled and 20 subjects com-
pleted the study. One subject died unexpectedly at
home, from unknown cause. Two subjects were lost to
follow up. We did not enroll any subjects with a diagno-
sis of diabetes. Table 1 shows demographic, PSG and
metabolic parameters for these subjects.
Sleep parameters and CPAP compliance
CPAP effectively reversed hypoxia in all subjects (nadir
O2 saturation 77 ± 3% at baseline and 89.3 ± 3 post
CPAP, p = 0.005) although mean O2 saturation did not
change significantly (Table 2). Subjects used CPAP for
165 ± 17 days and 5.3 ± 0.35 hrs/night. As shown in
Table 2, ESS decreased with CPAP therapy. However,
subjects as a group experienced weight gain after CPAP
treatment compared to baseline with a mean difference
of 1.6 Kg (p < 0.05) or 0.6 Kg/m
2 (p = 0.06). Systolic
blood pressure, diastolic blood pressure and heart rate
remained unchanged throughout the study period.
Glucose, insulin and insulin resistance
Fasting and postprandial glucose levels were unchanged
after CPAP use compared to baseline (Figure 1A). Fast-
ing insulin levels increased significantly after CPAP use
(Figure 1B). However postprandial and AUC0-120 insulin
remained unchanged compared to baseline (baseline
insulin AUC0-120 549 ± 129 μU*h/mL, post-CPAP
insulin AUC0-120 491 ± 56 μU*h/mL; p = 0.7). Insulin
resistance increased as measured by HOMA-IR,
QUICKI and ISI, although it only reached significance
for the first two indices (Table 2).
Active ghrelin and adipokine levels
Fasting active ghrelin levels decreased significantly after
CPAP use. However, postprandial active ghrelin levels
and active ghrelin AUC0-120 remained unchanged com-
pared to baseline (Figure 1C). Circulating leptin, adipo-
nectin and resistin levels remained unchanged after
CPAP use (Table 2).
Correlation and regression analyses between changes in
body weight, hormones and sleep parameters
Changes in BMI were directly correlated with changes
in insulin levels and in insulin resistance as measured by
HOMA-IR. Changes in ghrelin levels were inversely cor-
related with changes in insulin resistance, although
there was no correlation between changes in ghrelin and
changes in BMI or any of the other parameters mea-
sured (Table 3). On regression analyses, changes in BMI
predicted changes in insulin (B = 4.9 ± 2, p = 0.03),
insulin resistance (B = 1.75 ± 0.65, p = 0.02) and leptin
( B=2 . 2±1 ,p=0 . 0 4 6 )b u tn o to ng h r e l i n( B=3 8±
72, p = 0.61), adiponectin (B = -0.02 ± 1, p = 0.98) or
resistin (B = -0.09 ± 0.25, p = 0.74). Nadir SpO2 did not
predict any of the outcome variables (B = 0.8 ± 0.78, p
Table 1 Baseline Subjects Characteristics (n = 20)
Age (yrs) 59.7 ± 2
Body weight (Kg) 108 ± 5.3
BMI (Kg/m
2) 36.5 ± 1.8
Race (W, AA, H) 14, 4, 2
Male/Female 17/3
Leptin (ng/dL) 22.7 ± 6
Active ghrelin (pg/mL) 131 ± 48
Insulin (mU/mL) 22 ± 3
Adiponectin (ng/mL) 8.3 ± 1.2
Resistin (ng/mL) 3.1 ± 0.4
Glucose (mg/dL) 105 ± 4
QUICKI 0.31 ± 0.008
ISI 2.6 ± 0.55
HOMA-IR 5.9 ± 1
ESS 14.6 ± 1
AHI (episodes/hr) 50 ± 6
Lowest O2 sat. (%) 77 ± 3
Mean O2 sat. (%) 91.9 ± 0.9
Data shown are mean +/- SEM. BMI: Body mass index, W: White, AA: African
American, H: Hispanic, QUICKI: quantitative insulin sensitivity check index, ISI:
Insulin sensitivity index, HOMA-IR: homeostasis model assessment, ESS:
Epworth Sleepiness Scale, AHI: Apnea/Hypopnea Index.
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IR; B = 0.46 ± 0.39, p = 0.26 for leptin; B = -0.36 ± 24,
p = 0.17 for ghrelin; B = 0.34 ± 0.42, p = 0.44 for adipo-
nectin and B = -0.09 ± 0.095, p = 0.37 for resistin).
Baseline AHI correlated with changes in ESS (r -0.57, p
0.009) but was not correlated with CPAP use, changes
in nadir or mean O2 or any of the other metabolic para-
meters. Baseline ESS did not correlate with baseline
HOMA-IR.
Subgroup analyses
To determine the effect of weight changes in the other
parameters measured, we analyzed separately the data
from those subjects who gained a significant amount of
weight (defined as an increase ≥2% of their initial body
weight, n = 8) and those whose body weight remained
stable (n = 12). There were no significant differences at
baseline between the two groups and none of the groups
experienced significant changes in blood pressure or
heart rate (data not shown). Leptin, resistin and adipo-
nectin levels after CPAP remained stable in both groups
compared to baseline (Figure 2A).
Fasting insulin levels were significantly increased in
subjects who experienced weight gain but remained
stable in those subjects with stable body weight. Fasting
glucose levels remained unchanged in weight stable indi-
viduals and tended to increase in subjects experiencing
weight gain but it did not reach statistical significance
(Figure 2B). Postprandial and AUC0-120 insulin and glu-
cose levels remained unchanged in both groups after
CPAP use (Figure 2C). Fasting ghrelin levels decreased in
both groups; although it did not reach statistical signifi-
cance. Insulin resistance as measured by HOMA-IR, ISI
and QUICKI remained unchanged in subjects with stable
body weight. However, it was significantly increased in
the weight gain group (Figure 2D).
Discussion
Our study suggests that glucose metabolism is disturbed
in obese patients with OSA and that weight change
rather than hypoxia is the major long-term modulating
factor in insulin resistance after CPAP treatment in this
population. These findings also suggest that CPAP alone
may not reduce body weight, and that in the face of
weight gain CPAP treatment may not reduce insulin
resistance and leptin or increase adiponectin in obese
subjects. The results of our regression analyses where
the predictive value of BMI and nadir SpO2 was
explored support this hypothesis given that changes in
BMI but not changes in nadir SpO2 predicted changes
in insulin, insulin resistance and leptin.
We did not observe any changes in blood pressure, or
heart rate after CPAP treatment in contrast to what
most [15-17] but not all studies [18-20] have reported.
Possible explanations for this discrepancy include: 1) A
higher body weight in our cohort compared to others or
the fact that body weight remained stable or increased
in our cohort. This could have negated the beneficial
effects of CPAP on these outcomes as suggested by a
previous report that showed that the course of hyperten-
sion in OSA is more closely linked to weight loss than
to elimination of sleep apnea by CPAP [16]; 2) Different
duration of CPAP treatment (6 months in our study v.
1-2 months in other reports); 3) Time of the day at
which BP was assessed given that CPAP effects on BP
a r er e p o r t e d l ym o r ep r o n o u n c e dd u r i n gs l e e pa n dw e
monitored our patients in the morning; 4) Methods of
BP measurement since this factor has been shown to
influence results [17]; and 5) We did not power the
study to detect differences in these outcomes so a nega-
tive result should be interpreted with caution.
Several reports have demonstrated an association
between OSA and insulin resistance [2,21-24]. However,
the effect of CPAP therapy on insulin resistance remains
controversial (recently reviewed in [25]). Some reports
failed to detect an improvement in insulin sensitivity
[26], others showed an improvement in glucose levels
only during sleep [27,28] and others showed an almost
immediate improvement, especially in non-obese
patients [13]. In our study, we found increased insulin
resistance after 6 months of CPAP use. This insulin
resistance was associated with weight gain indicating
Table 2 Sleep and metabolic parameters before and after
CPAP use
Baseline Post-CPAP p value
CPAP pressure (cm H2O) 10 ± 3.2
CPAP use (days) 165 ± 17
CPAP use (Hrs/day) 5.3 ± 0.35
ESS 14.6 ± 1 9.5 ± 1 0.002
Lowest O2 sat. (%) 77 ± 3 89.3 ± 3 0.005
Mean O2 sat. (%) 93.2 ± 0.7 93.8 ± 0.62 0.5
Systolic blood pressure (mmHg) 124 ± 3 129 ± 4 0.07
Diastolic blood pressure (mmHg) 76 ± 2 76 ± 2 0.99
Heart rate (bpm) 77 ± 3 72 ± 3 0.27
Body weight (Kg) 108 ± 5.3 109.6 ± 5.4 0.04
BMI (Kg/m
2) 36.5 ± 1.8 37.1 ± 1.8 0.06
Leptin (ng/dL) 22.7 ± 6 21.6 ± 4 0.61
Adiponectin (ng/mL) 8.3 ± 1.2 8.2 ± 1.2 0.94
Resistin (ng/mL) 3.1 ± 0.4 3.2 ± 0.4 0.79
HOMA-IR 5.9 ± 1 7.5 ± 1.2 0.04
ISI 2.6 ± 0.55 2.1 ± 0.33 0.09
QUICKI 0.31 ± 0.008 0.3 ± 0.006 0.02
Significant differences compared to baseline (p ≤ 0.05) appear in bold. ESS:
Epworth Sleepiness Scale, QUICKI: quantitative insulin sensitivity check index,
ISI: Insulin sensitivity index, HOMA-IR: homeostasis model assessment.
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Figure 1 Glucose (A), insulin (B) and active ghrelin levels (C) during OGTT before and after CPAP. *p < 0.05 for baseline values. p values
for fasting and AUC0-120 glucose were 0.88 and 0.24 respectively. p value for insulin AUC0-120 was 0.7; p value for ghrelin AUC0-120 was 0.4.
Table 3 Correlation analysis for changes in weight, hormone levels and sleep parameters [r(pvalue)]
HOMA-
IR
Ghrelin Leptin Insulin Adiponectin
nectin
Resistin ESS CPAP use
BMI 0.56
(0.01)
0.04
(0.87)
0.32
(0.17)
0.58
(0.008)
-0.24
(0.29)
-0.35
(0.13)
-0.02
(0.95)
0.02
(0.94)
HOMA-
IR
-0.51
(0.026)
0.13
(0.59)
0.95
(0.001)
-0.04
(0.9)
-0.32
(0.18)
-0.01
(0.98)
0.22
(0.35)
Ghrelin 0.18
(0.46)
-0.43
(0.066)
-0.27
(0.26)
0.11
(0.68)
0.09
(0.7)
-0.19
(0.43)
Leptin 0.22
(0.34)
0.21
(0.38)
0.11
(0.65)
0.15
(0.53)
-0.27
(0.26)
Insulin -0.17
(0.48)
0.4
(0.08)
-0.07
(0.8)
0.21
(0.37)
Adipon
ectin
0.24
(0.33)
0.13
(0.59)
-0.11
(0.65)
Resistin 0.04
(0.87)
-0.26
(0.28)
Significant correlations (p ≤ 0.05) appear in bold. ISI: Insulin sensitivity index, HOMA-IR: homeostasis model assessment. Changes in all variables including ESS
were use for analysis.
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lin resistance in obese CPAP-treated patients with OSA.
These results are in agreement with those reported by
Ip and others [21]. The apparently divergent findings
between our results and those previously reporting an
improvement in insulin sensitivity also may relate to dif-
ferences in sample timing. Our assessment was done 6
months after starting treatment whereas most reports
have been done between 48 hours and 3 months after
starting CPAP. It is possible that CPAP use has only a
transient effect on insulin sensitivity and that changes in
body weight are a much more important factor in the
long-term regulation of insulin sensitivity.
Ghrelin is an appetite-increasing hormone postulated
as a contributor to OSA-associated obesity as ghrelin
levels were elevated in one report [14]. In the same
study, fasting total (the sum of active and inactive) ghre-
lin levels decreased after 2 days of CPAP. Another study
reported equivalent fasting total ghrelin levels in obese
subjects with OSA and BMI matched controls without
OSA [29]. In our study, we measured active ghrelin
instead of total ghrelin because 75% of the circulating
peptide is biologically inactive and the ratio between
inactive and active ghrelin changes in different clinical
scenarios [9]. Since ghrelin is suppressed by food intake,
ghrelin levels were measured while fasting and during
the OGTT. Our results show that 6 months of CPAP
treatment significantly decreased fasting active ghrelin
levels but that postprandial levels of this hormone
remained unchanged. This is in agreement with a recent
report of fasting active ghrelin levels being decreased by
CPAP after one month of treatment [30]. Although
ghrelin inversely correlates with body weight in the set-
ting of obesity, we did not found any association
between changes in ghrelin levels and changes in BMI,
CPAP use or changes in the ESS in this setting. Ghrelin
correlated with changes in insulin resistance, suggesting
that other factors besides body weight may play a role
HOMA-IR SI QUICKI
-4
-2
0
2
4
6
8
Weight stable 
Weight gain
**
* **
D
(pg*hr/mL)        ( U*hr/mL)     (mg*hr/mL)
Ghrelin AUC Insulin AUC Glucose AUC
-300
-200
-100
0
100
200
Weight stable
Weight gain
C
(Kg)       (ng/dL)    (ng/mL)       (ng/mL)
Weight Leptin AdiponectinResistin
-4
-2
0
2
4
6 Weight stable
Weight gain **
A
U/mL)         (pg/mL)          (mg/dL)
Insulin Ghrelin Glucose
-120
-100
-80
-60
-40
-20
0
20
40
Weight stable
Weight gain
**
B
Figure 2 Body weight, adipokines (A), glucose, insulin (B-C) and insulin resistance changes (D) after CPAP according to changes in
body weight. Weight gain was defined as an increase ≥2% of their initial body weight (n = 8). Weight stable was defined as a weight
fluctuation ≥2% (n = 12). *p < 0.05, **p < 0.01 compared to other group.
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Insulin administration has been shown to suppress cir-
culating ghrelin levels in some [31] but not all studies
[32]. Plasma insulin levels and insulin resistance corre-
late inversely with ghrelin. This association was BMI-
independent in some studies [33]. However in a study
using euglycemic hyperinsulinemic clamp method, insu-
lin sensitivity did not correlate with ghrelin concentra-
tions [34]. Independent of metabolic factors, ghrelin
may also act as a sleep-inducing hormone. Ghrelin levels
increase after sleep deprivation [35] and slow wave sleep
is enhanced after ghrelin administration [36]. Based on
these data, we postulate that the fasting ghrelin level
increase seen in patients with OSA is a compensatory
response to poor-quality sleep and could explain why
fasting ghrelin levels decreased after CPAP use.
Leptin is secreted by adipocytes in proportion to body
fat, being elevated in obese individuals and decreasing
with weight loss. Leptin-deficient animals exhibit
respiratory depression and CO2 retention. Leptin admin-
istration to these animals increases minute ventilation
and improves lung mechanics [37]. These animal experi-
ments suggest that an increase in leptin levels in
patients with OSA may represent a compensatory
response to hypoxia. Consistent with this hypothesis,
elevated leptin has been described in OSA patients com-
pared to BMI-matched controls. This elevation in leptin
was reversed by CPAP treatment [14,38], although this
was associated with a decrease in fat accumulation in
some studies [39] that may have accounted at least par-
tially for the changes in leptin. Others have reported
that leptin levels are similar in obese OSA patients
when compared to non-OSA controls and that these
levels do not change significantly after 1 month or 1
year of CPAP [30,40]. In agreement with the latter
study, our data showed that leptin levels remained stable
after CPAP use. Taken together, these data suggest that
if CPAP has an effect on leptin levels, it is short-lasting.
The role of resistin in diabetes remains a matter of
debate. Circulating resistin levels directly correlate with
BMI and have been shown to decrease with weight loss
[41]. Resistin also directly correlates with insulin resis-
tance in some studies, but not in others [42,43]. In our
study, resistin levels did not change after 6 months of
CPAP and its levels did not correlate with changes in
body weight, insulin and other adipokines or sleep para-
meters. In agreement with our data, resistin levels were
stable after 2 days and 2 months of CPAP use in a
group of subjects with OSA, suggesting that resistin is
unlikely to play an important role in the insulin resis-
tance or obesity seen in OSA [13].
Adiponectin is decreased in obese individuals and in
those with type 2 diabetes. It is thought to play a role in
many of the metabolic complications suffered by these
patients including metabolic syndrome and cardiovascu-
lar disease. However, its role in patients with OSA
remains controversial. Elevated adiponectin was found
in subjects with OSA when compared with non-OSA
controls in one report and diminished in another
[44,45]. In agreement with prior reports of adiponectin
levels after CPAP use [46], we report here that adipo-
nectin levels remained unchanged after 6 months of
CPAP treatment. Harsch et al. had previously reported a
decrease in adiponectin levels after 48 hrs of CPAP use
but levels returned to baseline at 3 months. The data
suggest that chronic CPAP treatment does not play a
role in the regulation of adiponectin levels.
Although the study was powered a priori using pub-
lished data [13,14], the small sample size is a limitation
of this study. Other limitations include the lack of data
on changes in dietary habits; physical activity and body
composition that could help us better understand the
effects of CPAP on hormonal regulation. Also, it would
have been useful to compare changes in body weight
and other parameters with a non-interventional group
of controls. However, such a group was not included in
our design because these subjects have a clinical indica-
tion for CPAP use and delaying its use would have been
unethical. Our study was powered to detect significant
differences in insulin resistance and ghrelin levels. Con-
sequently, we cannot conclude that the lack of changes
in leptin, adiponectin and resistin levels in this relatively
small sample would not be seen in a larger sample. Sig-
nificant associations detected during simple correlation
analysis should be interpreted with caution given the
number of variables compared which increase the
chance for a type I error. Future studies should include
a larger number of patients along with an assessment of
dietary habits; physical activity, energy expenditure,
anthropometrics (i.e. waist-to-hip ratio) and body com-
position in order to better understand the effects of
CPAP in this setting.
Conclusions
In summary, six months of CPAP treatment did not
improve insulin resistance in obese subjects. In fact, in
subjects who gained weight during the study, insulin
resistance increased suggesting that changes in insulin
sensitivity induced by CPAP in this setting are mainly
determined by changes in body weight. CPAP treatment
induced a decrease in fasting ghrelin levels, although
body weight increased in most subjects. Adipokines
such as leptin, adiponectin and resistin also appear to be
influenced much more by adiposity rather than hypoxia.
The fact that these adipokines remain unchanged after 6
months of CPAP treatment suggests that they are unli-
kely to play an important role in the development of the
metabolic complications seen in the setting of OSA.
Garcia et al. Respiratory Research 2011, 12:80
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Page 7 of 9When obese patients with OSA are treated with CPAP,
other measurements targeting obesity should also be
pursued.
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